ANGO - AngioDynamics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
21.50
-0.03 (-0.12%)
As of 11:17AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close21.53
Open21.41
Bid21.49 x 900
Ask21.52 x 1200
Day's Range21.33 - 21.90
52 Week Range18.11 - 25.48
Volume46,667
Avg. Volume201,098
Market Cap800.328M
Beta (3Y Monthly)0.73
PE Ratio (TTM)13.36
EPS (TTM)1.61
Earnings DateSep 25, 2019 - Sep 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.67
Trade prices are not sourced from all markets
  • Thomson Reuters StreetEvents7 days ago

    Edited Transcript of ANGO earnings conference call or presentation 10-Jul-19 12:00pm GMT

    Q4 2019 AngioDynamics Inc Earnings Call

  • AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates
    Zacks8 days ago

    AngioDynamics (ANGO) Q4 Earnings Miss, Revenues Top Estimates

    AngioDyamics (ANGO) gains from solid segmental contributions in fourth-quarter fiscal 2019.

  • AngioDynamics (ANGO) Q4 2019 Earnings Call Transcript
    Motley Fool8 days ago

    AngioDynamics (ANGO) Q4 2019 Earnings Call Transcript

    ANGO earnings call for the period ending June 30, 2019.

  • AngioDynamics completes $100 million turnaround
    American City Business Journals9 days ago

    AngioDynamics completes $100 million turnaround

    Sales increased by $15 million last year to $359.5 million, with about half of that growth coming from international customers.

  • AngioDynamics (ANGO) Lags Q4 Earnings Estimates
    Zacks9 days ago

    AngioDynamics (ANGO) Lags Q4 Earnings Estimates

    AngioDynamics (ANGO) delivered earnings and revenue surprises of -3.85% and 3.72%, respectively, for the quarter ended May 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Is AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Paid At A Competitive Rate?
    Simply Wall St.9 days ago

    Is AngioDynamics, Inc.'s (NASDAQ:ANGO) CEO Paid At A Competitive Rate?

    Jim Clemmer has been the CEO of AngioDynamics, Inc. (NASDAQ:ANGO) since 2016. First, this article will compare CEO...

  • Business Wire9 days ago

    AngioDynamics Reports Fiscal 2019 Fourth Quarter and Full-Year Financial Results

    Fiscal 2019 Fourth Quarter Highlights

  • ACCESSWIRE9 days ago

    AngioDynamics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / July 10, 2019 / AngioDynamics, Inc. (NASDAQ: ANGO ) will be discussing their earnings results in their 2019 Fourth Quarter Earnings to be held on July 10, 2019 at 8:00 AM Eastern ...

  • Benzinga10 days ago

    Q4 Earnings Outlook For AngioDynamics

    AngioDynamics (NASDAQ: ANGO ) unveils its next round of earnings this Wednesday, July 10. Get prepared with Benzinga's ultimate preview for AngioDynamics's Q4 earnings. Earnings and Revenue Wall Street ...

  • AngioDynamics' bold move: get smaller (for now)
    American City Business Journals22 days ago

    AngioDynamics' bold move: get smaller (for now)

    CEO Jim Clemmer was hired in 2016 to turn around AngioDynamics. The plan: Sell off some legacy products and invest in next-generation oncology technology to eventually make the company even bigger.

  • Is AngioDynamics, Inc. (ANGO) A Good Stock To Buy?
    Insider Monkey23 days ago

    Is AngioDynamics, Inc. (ANGO) A Good Stock To Buy?

    Out of thousands of stocks that are currently traded on the market, it is difficult to identify those that will really generate strong returns. Hedge funds and institutional investors spend millions of dollars on analysts with MBAs and PhDs, who are industry experts and well connected to other industry and media insiders on top of that. Individual investors can piggyback […]

  • Business Wire29 days ago

    AngioDynamics to Report Fiscal 2019 Fourth Quarter and Full-Year Financial Results on July 10, 2019

    AngioDynamics, Inc. , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it will report financial results for the fourth quarter and fiscal year 2019 before the market open on Wednesday, July 10, 2019.

  • AngioDynamics moving 125 employees into downtown Glens Falls
    American City Business Journalslast month

    AngioDynamics moving 125 employees into downtown Glens Falls

    AngioDynamics will lease the 9th floor of the 10-story Monument Square building in a plan that will bring 125 employees into downtown Glens Falls. The medical device maker is taking approximately 15,000 square feet of office space to accommodate personnel, most of whom previously worked at 10 Glens Falls Technical Park, the former Navilyst building that was sold to Medline Industries last week for $5.75 million. The move is part of AngioDynamics' strategy to improve communication, restructure its manufacturing operations and build a stronger corporate culture, said Dave Helsel, senior vice president of global operations, research and development.

  • AngioDynamics Divests NAMIC Portfolio to Medline Industries
    Zackslast month

    AngioDynamics Divests NAMIC Portfolio to Medline Industries

    The NAMIC fluid management portfolio sale clears all of AngioDynamics' (ANGO) outstanding debt.

  • Business Wirelast month

    AngioDynamics to Present at the Raymond James Life Sciences and MedTech Conference

    AngioDynamics, Inc.  , a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that Jim Clemmer, President and Chief Executive Officer, will present at the Raymond James Life Sciences and MedTech Conference at 1:50 p.m.

  • Business Wire2 months ago

    AngioDynamics Completes Sale of NAMIC® Fluid Management Portfolio to Medline Industries, Inc.

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that it closed the previously announced sale of its NAMIC® fluid management portfolio to Medline Industries, Inc. on May 31, 2019 for $167.5 million. AngioDynamics has used a portion of the approximately $160.0 million in net proceeds to pay down all of its outstanding debt. “We are very pleased to have completed the divestiture of the NAMIC fluid management business, which is a critical step in our ongoing portfolio optimization efforts,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics.

  • Business Wire2 months ago

    AngioDynamics to Ring NASDAQ Closing Bell to Celebrate the 15th Anniversary of its Listing on the Exchange

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that representatives of the Company will ring the NASDAQ Stock Market closing bell on Tuesday, May 28, 2019 at 4:00 p.m. ET to commemorate the 15-year anniversary of the Company’s listing on the exchange. “NASDAQ has provided AngioDynamics with a robust platform to access the public equity markets and connect with potential shareholders and investors,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics.

  • AngioDynamics IDE Application for NanoKnife Gets FDA Nod
    Zacks2 months ago

    AngioDynamics IDE Application for NanoKnife Gets FDA Nod

    AngioDynamics' (ANGO) pilot study is intended to support the approval of a future PMA in the United States.

  • Business Wire2 months ago

    AngioDynamics Receives FDA Approval to Initiate Pilot Study for the Use of NanoKnife® to Treat Prostate Cancer

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, peripheral vascular disease, and oncology, today announced that the United States Food and Drug Administration (FDA) approved the Company’s investigational device exemption (IDE) application for its NanoKnife® Irreversible Electroporation pilot study for the ablation of prostate cancer tissue in low-risk patients. The prospective, non-randomized pilot study includes six subjects at up to three clinical sites.

  • Business Wire2 months ago

    AngioDynamics Announces First Patient Enrolled in NanoKnife® DIRECT Clinical Study for the Treatment of Stage III Pancreatic Cancer

    The DIRECT Study supports a proposed expanded indication for the NanoKnife System in the treatment of Stage III pancreatic cancer. The first patient enrollment closely follows the United States Food and Drug Administration’s (FDA) April 1, 2019 approval of AngioDynamics’ investigational device exemption (IDE) application.

  • Here’s What Hedge Funds Think About AngioDynamics, Inc. (ANGO)
    Insider Monkey2 months ago

    Here’s What Hedge Funds Think About AngioDynamics, Inc. (ANGO)

    World-class money managers like Ken Griffin and Barry Rosenstein only invest their wealthy clients' money after undertaking a rigorous examination of any potential stock. They are particularly successful in this regard when it comes to small-cap stocks, which their peerless research gives them a big information advantage on when it comes to judging their worth. […]

  • Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?
    Zacks3 months ago

    Why Is AngioDynamics (ANGO) Down 12.1% Since Last Earnings Report?

    AngioDynamics (ANGO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Benzinga3 months ago

    The Daily Biotech Pulse: Hookipa To Debut, Mustang Bio Skyrockets, AngioDynamics Sheds Portfolio

    Here's a roundup of top developments in the biotech space over the last 24 hours: No biotech stocks hit 52-week highs on Thursday. Down In The Dumps (Biotech stocks hitting 52-week lows on April 17) ABIOMED, ...

  • AngioDynamics will sell Namic business for $167.5 million
    American City Business Journals3 months ago

    AngioDynamics will sell Namic business for $167.5 million

    The sale is expected to close by the end of May. Once that occurs, 330 to 350 AngioDynamics employees are expected to join Medline Industries Inc., a privately-held company headquartered near Chicago.

  • Business Wire3 months ago

    AngioDynamics Announces Agreement to Sell NAMIC® Fluid Management Business to Medline Industries, Inc. for $167.5 Million

    AngioDynamics, Inc. (ANGO), a leading provider of innovative, minimally invasive medical devices for oncology, vascular access, and peripheral vascular disease, today announced that it has entered into a definitive agreement to sell its NAMIC® fluid management portfolio to Medline Industries, Inc. for $167.5 million, subject to customary closing conditions including antitrust review under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction consists of AngioDynamics’ NAMIC brand and its extensive offering of manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories.